DAY 3Thursday, 3 December 2026 - America/Los_Angeles (UTC-08:00)

Despite promising trial results, many biostimulant and biological products struggle to achieve commercial success. This critical gap between laboratory performance and market adoption continues to challenge the industry, leaving significant value unrealized and innovation potential untapped.

Join us for an essential workshop that tackles this persistent challenge head-on. Our distinguished panel of Strategic Advisory Board members will explore the underlying factors that contribute to commercialization failures, share real-world insights from across the value chain, and identify actionable strategies to bridge the gap between product efficacy and market success.

Moderated by Dr. Steve Byrne of Byrne Advisory and former Managing Director of US Chemicals Equity Analysis at Bank of America, this interactive session will provide participants with:

• Critical insights into why technically sound products fail to gain market traction
• Practical strategies for improving commercialization success rates
• Industry perspectives from experienced leaders who have navigated these challenges
• Actionable takeaways to apply immediately within your organization

Whether you're developing the next generation of biological solutions, bringing products to market, or investing in agricultural innovation, this workshop will equip you with the knowledge and strategies needed to improve your odds of commercial success.

Panel details and speaker bios will be announced shortly.

Don't miss this opportunity to learn from industry leaders and gain the competitive edge your biologicals program needs. Invitation only.